Funding for this research was provided by:
Telethon Kids Institute (Infectious Diseases Research Focus Area Working Group, Seed Funding Award)
Received: 22 December 2019
Accepted: 18 October 2020
First Online: 25 November 2020
Ethics approval and consent to participate
: Ethical approval was obtained from the the PNGIMR Institutional Review Board (IRB 1515) and the PNG Medical Research Advisory Committee (MRAC 16.13). The study was conducted according to Declaration of Helsinki International Conference on Harmonization Good Clinical Practice (ICH-GCP) and local ethical guidelines.Written informed consent was obtained from all study participants before screening and enrolment in the study.
: Not applicable.
: DL has received support from Pfizer Australia to attend conferences, an honorarium from Merck Vaccines to give a seminar at their offices in Pennsylvania and support from Merck Vaccines to attend a conference; and is an investigator on an investigator-initiated research grant that was funded by Pfizer Australia. PR has received non-financial support from Pfizer, grants from GlaxoSmithKline, grants from Pfizer, and non-financial support from GlaxoSmithKline for work outside the submitted work. WP and AVDB have received funding from Pfizer Australia to attend research conferences. AVDB has conducted contract work for Pfizer Inc. as a consultant with P95 Epidemiology and Pharmacovigilance outside the scope and independent of the submitted work.